Verena Kraus1, Rajneesh Srivastava, Sudhakar Reddy Kalluri, Ulrich Seidel, Markus Schuelke, Mareike Schimmel, Kevin Rostasy, Steffen Leiz, Stuart Hosie, Verena Grummel, Bernhard Hemmer. 1. From the Departments of Pediatrics (V.K.) and Neurology (R.S., S.R.K., V.G., B.H.), Klinikum rechts der Isar, Technische Universität, Munich; Department of Neuropediatrics (U.S., M.S.), Charité Universitätsmedizin, Berlin; Department of Pediatrics (M.S.), Hospital Augsburg, Germany; Department of Neuropediatrics (K.R.), University Hospital Innsbruck, Austria; Department of Pediatrics (S.L.), Hospital Dritter Orden, Munich; Department of Pediatric Surgery (S.H.), Städtisches Klinikum München GmbH, Klinikum Schwabing, Munich; and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Munich, Germany.
Abstract
OBJECTIVE: A serum antibody against the inward rectifying potassium channel KIR4.1 (KIR4.1-IgG) was recently discovered, which is found in almost half of adult patients with multiple sclerosis. We investigated the prevalence of KIR4.1-IgG in children with acquired demyelinating disease (ADD) of the CNS. We also compared antibody responses to KIR4.1 and myelin oligodendrocyte glycoproteins (MOGs), another potential autoantigen in childhood ADDs. METHODS: We measured KIR4.1-IgG by ELISA in children with ADD (n = 47), other neurologic disease (n = 22), and autoimmune disease (n = 22), and in healthy controls (HCs) (n = 18). One hundred six samples were also measured by capture ELISA. Binding of KIR4.1-IgG human subcortical white matter was analyzed by immunofluorescence. Anti-MOG antibodies were measured using a cell-based assay. RESULTS: KIR4.1-IgG titers were significantly higher in children with ADD compared with all control groups by ELISA and capture ELISA (p < 0.0001, p < 0.0001). Overall, 27 of 47 patients with ADD (57.45%) but none of the 62 with other neurologic disease or autoimmune disease or the HCs (0%) were KIR4.1-IgG antibody positive by ELISA. Sera containing KIR4.1-IgG stained glial cells in brain tissue sections. No correlation among KIR4.1-IgG, age, or MOG-IgG was observed in the ADD group. CONCLUSION: Serum antibodies to KIR4.1 are found in the majority of children with ADD but not in children with other diseases or in HCs. These findings suggest that KIR4.1 is an important target of autoantibodies in childhood ADD.
OBJECTIVE: A serum antibody against the inward rectifying potassium channel KIR4.1 (KIR4.1-IgG) was recently discovered, which is found in almost half of adult patients with multiple sclerosis. We investigated the prevalence of KIR4.1-IgG in children with acquired demyelinating disease (ADD) of the CNS. We also compared antibody responses to KIR4.1 and myelin oligodendrocyte glycoproteins (MOGs), another potential autoantigen in childhood ADDs. METHODS: We measured KIR4.1-IgG by ELISA in children with ADD (n = 47), other neurologic disease (n = 22), and autoimmune disease (n = 22), and in healthy controls (HCs) (n = 18). One hundred six samples were also measured by capture ELISA. Binding of KIR4.1-IgGhuman subcortical white matter was analyzed by immunofluorescence. Anti-MOG antibodies were measured using a cell-based assay. RESULTS:KIR4.1-IgG titers were significantly higher in children with ADD compared with all control groups by ELISA and capture ELISA (p < 0.0001, p < 0.0001). Overall, 27 of 47 patients with ADD (57.45%) but none of the 62 with other neurologic disease or autoimmune disease or the HCs (0%) were KIR4.1-IgG antibody positive by ELISA. Sera containing KIR4.1-IgG stained glial cells in brain tissue sections. No correlation among KIR4.1-IgG, age, or MOG-IgG was observed in the ADD group. CONCLUSION: Serum antibodies to KIR4.1 are found in the majority of children with ADD but not in children with other diseases or in HCs. These findings suggest that KIR4.1 is an important target of autoantibodies in childhood ADD.
Authors: Alberto Pérez-Samartín; Edith Garay; Juan Pablo H Moctezuma; Abraham Cisneros-Mejorado; María Victoria Sánchez-Gómez; Guadalupe Martel-Gallegos; Leticia Robles-Martínez; Manuel Canedo-Antelo; Carlos Matute; Rogelio O Arellano Journal: Neurochem Res Date: 2017-03-27 Impact factor: 3.996
Authors: Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz Journal: Acta Neuropathol Date: 2014-07-04 Impact factor: 17.088
Authors: Adipong Brickshawana; Shannon R Hinson; Michael F Romero; Claudia F Lucchinetti; Yong Guo; Mathias Buttmann; Andrew McKeon; Sean J Pittock; Min-Hwang Chang; An-Ping Chen; Thomas J Kryzer; James P Fryer; Sarah M Jenkins; Philippe Cabre; Vanda A Lennon Journal: Lancet Neurol Date: 2014-07-06 Impact factor: 44.182